Modelling and sample size reestimation for longitudinal count data with incomplete follow up

We consider modelling and inference as well as sample size estimation and reestimation for clinical trials with longitudinal count data as outcomes. Our approach is general but is rooted in design and analysis of multiple sclerosis trials where lesion counts obtained by magnetic resonance imaging are important endpoints. We adopt a binomial thinning model that allows for correlated counts with marginal Poisson or negative binomial distributions. Methods for sample size planning and blinded sample size reestimation for randomised controlled clinical trials with such outcomes are developed. The models and approaches are applicable to data with incomplete observations. A simulation study is conducted to assess the effectiveness of sample size estimation and blinded sample size reestimation methods. Sample sizes attained through these procedures are shown to maintain the desired study power without inflating the type I error. Data from a recent trial in patients with secondary progressive multiple sclerosis illustrate the modelling approach.

[1]  D. Ohlssen,et al.  A Bayesian hierarchical surrogate outcome model for multiple sclerosis , 2016, Pharmaceutical statistics.

[2]  Richard Nicholas,et al.  Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial , 2014, The Lancet.

[3]  Markus S. Mueller,et al.  Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  Heinz Schmidli,et al.  Robustness of methods for blinded sample size re‐estimation with overdispersed count data , 2013, Statistics in medicine.

[5]  David B. Dunson,et al.  Nonparametric Bayes modelling of count processes , 2013, 1307.2822.

[6]  R. Zivadinov,et al.  Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis , 2013, Annals of neurology.

[7]  A. Petkau,et al.  MRI-based clinical trials in relapsing–remitting MS: new sample size calculations based on a longitudinal model , 2012, Multiple sclerosis.

[8]  Dean Vrecko,et al.  A longitudinal model for magnetic resonance imaging lesion count data in multiple sclerosis patients , 2012, Statistics in medicine.

[9]  Jeffrey A. Cohen,et al.  Multiple sclerosis therapeutics, fourth edition , 2011 .

[10]  Gary K Grunwald,et al.  A statistical model for under‐ or overdispersed clustered and longitudinal count data , 2011, Biometrical journal. Biometrische Zeitschrift.

[11]  Maria Pia Sormani,et al.  Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis , 2011, Multiple sclerosis.

[12]  David H. Miller,et al.  A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis , 2011, Multiple sclerosis.

[13]  Jeffrey A. Cohen,et al.  Multiple Sclerosis Therapeutics: Abbreviations list , 2011 .

[14]  Heinz Schmidli,et al.  Blinded sample size reestimation with count data: Methods and applications in multiple sclerosis , 2010, Statistics in medicine.

[15]  F Barkhof,et al.  Ibudilast in relapsing-remitting multiple sclerosis , 2010, Neurology.

[16]  P. Vermersch,et al.  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[17]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[18]  T Friede,et al.  Blinded Sample Size Reestimation with Negative Binomial Counts in Superiority and Non-inferiority Trials , 2010, Methods of Information in Medicine.

[19]  A new serially correlated gamma-frailty process for longitudinal count data. , 2009, Biostatistics.

[20]  H. Müller,et al.  Modelling sparse generalized longitudinal observations with latent Gaussian processes , 2008 .

[21]  C. Genest,et al.  A Primer on Copulas for Count Data , 2007, ASTIN Bulletin.

[22]  A. Petkau,et al.  Application of hidden Markov models to multiple sclerosis lesion count data , 2005, Statistics in medicine.

[23]  D. Paty,et al.  Interferon beta-1b in secondary progressive MS , 2004, Neurology.

[24]  B. Sutradhar.  An Overview on Regression Models for Discrete Longitudinal Responses , 2003 .

[25]  R. Henderson,et al.  A serially correlated gamma frailty model for longitudinal count data , 2003 .

[26]  Christina Gloeckner,et al.  Modern Applied Statistics With S , 2003 .

[27]  Jeffrey A. Cohen,et al.  Benefit of interferon &bgr;-1a on MSFC progression in secondary progressive MS , 2002, Neurology.

[28]  Analysing longitudinal count data with overdispersion , 2002 .

[29]  F Barkhof,et al.  The role of MRI as a surrogate outcome measure in multiple sclerosis , 2002, Multiple sclerosis.

[30]  O. Favorova,et al.  Randomized study of antibodies to IFN-g and TNF-a in secondary progressive multiple sclerosis , 2001 .

[31]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[32]  O. Favorova,et al.  Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. , 2001, Multiple sclerosis.

[33]  F. Barkhof,et al.  Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials , 1999, Journal of the Neurological Sciences.

[34]  R I Grossman,et al.  Perspectives on multiple sclerosis. , 1998, AJNR. American journal of neuroradiology.

[35]  A. Thompson,et al.  Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups , 1998, Journal of neurology, neurosurgery, and psychiatry.

[36]  J. Simon.  Contrast‐enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis , 1997, Journal of magnetic resonance imaging : JMRI.

[37]  Mohamed Alosh,et al.  An integer-valued pth-order autoregressive structure (INAR(p)) process , 1990, Journal of Applied Probability.

[38]  J. Wittes,et al.  The role of internal pilot studies in increasing the efficiency of clinical trials. , 1990, Statistics in medicine.

[39]  Mohamed Alosh,et al.  FIRST‐ORDER INTEGER‐VALUED AUTOREGRESSIVE (INAR(1)) PROCESS , 1987 .

[40]  E. McKenzie,et al.  Autoregressive moving-average processes with negative-binomial and geometric marginal distributions , 1986, Advances in Applied Probability.

[41]  Fw Fred Steutel,et al.  Discrete analogues of self-decomposability and stability , 1979 .

[42]  Peter A. W. Lewis,et al.  Discrete Time Series Generated by Mixtures. I: Correlational and Runs Properties , 1978 .

[43]  Peter A. W. Lewis,et al.  Discrete Time Series Generated by Mixtures Ii: Asymptotic Properties , 1978 .

[44]  J. Griffiths.  The Theory of Stochastic Processes , 1967 .